Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QQ21: sourced facts only. name: "Structure activity relationship investigation demonstrated that compound QQ21 showed significant improved STING inhibition activity in mouse RAW-Lucia™ ISG cells with an IC50 value of 86 nM, which is 8-fold of the efficacy of H151." [PMID:41534479]; target: "Structure activity relationship investigation demonstrated that compound QQ21 showed significant improved STING inhibition activity in mouse RAW-Lucia™ ISG cells with an IC50 value of 86 nM, which is 8-fold of the efficacy of H151." [PMID:41534479]; developer: "Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, PR China." [PMID:41534479]; stage: "In cisplatin-induced acute kidney injury (AKI) mouse model, QQ21 significantly prevented kidney function damage and inflammation." [PMID:41534479]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QQ21.